Nurosym vs Truvaga Plus: published evidence against a two minute session

Nurosym is the strongest evidence position in consumer vagus nerve stimulation, and the reason is specific. A sham controlled randomized trial in postural tachycardia syndrome, published in JACC Clinical Electrophysiology, names the Parasym device in its full text methods rather than describing a generic ear clip. A long COVID pilot in Frontiers in Neurology names the Parasym system too. Both are small, at 12 active and 14 sham in the POTS trial.

The company also claims 60 plus studies. That wider figure is not published as a checkable list, so we treat it as a marketing claim and the two named trials as the fact.

Truvaga has no trial of its own. A PubMed search returns nothing. Its parent company electroCore does hold five FDA clearances, and all five belong to gammaCore, a prescription device for headache conditions with 127 records on PubMed. That is genuine credibility for the company and it does not transfer to this product.

Neither device is FDA cleared. Nurosym is CE certified, which is the European medical device route and a real regulatory step, not the same as an FDA clearance. How much the evidence base can carry is worth reading before spending either amount.

Thirty to sixty minutes a day, on a wired clip, with nothing to look at and no app to guide you. That is what the trials used and it is what the manufacturer instructs.

Two minutes, standing at a mirror, is what Truvaga asks. It is the shortest session in the category by a wide margin.

The trap here is buying the evidence and then not doing the protocol the evidence came from. A device used for ten minutes when the trial used sixty is not the intervention that was studied. If you already know your evenings do not have an hour in them, that is worth weighing before the purchase rather than after.

Nurosym is a single payment. There is no app and no subscription, and the manufacturer says the battery lasts weeks between charges. The replaceable part is the earpiece electrode, covered for six months against two years on the device. In the US it is HSA and FSA eligible, which for some buyers takes a meaningful bite out of the $900.

Truvaga is $499 with a free app and no subscription. Its recurring cost is the conductive electrode spray, which the company says lasts around two months a bottle.

Both are devices you buy once and then own. Neither has an ongoing cost worth building a spreadsheet over.

Pick Nurosym if you want the device named in trial methods, you want CE medical device certification, you want nothing further to pay, or you are dealing with something specific like POTS or long COVID where the published work sits.

Pick Truvaga if adherence is your real constraint, you would rather stimulate at the neck than clip something to your ear, or you want to spend $401 less.

Consider a third option if both prices feel steep for something you are still testing. A worn neck device starts at $259 and asks for four to twenty minutes.